查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433445

全球戊型肝炎诊断测试市场 2023-2030

Global Hepatitis E Diagnostic Tests Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 240 Pages | 商品交期: 2-3个工作天内

价格

全球戊型肝炎诊断测试市场预计在预测期内（2024-2031年）CAGR为7.40%。市场的成长归因于对全球健康关注的需求。戊型肝炎作为主要公共卫生问题的全球盛行率和重要性推动了诊断测试的不断增长和接受，以有效管理和尽量减少疾病对公共卫生的影响。根据美国国立卫生研究院(gov.) 2023 年5 月的数据，戊型肝炎是由戊型肝炎病毒(HEV) 引起的肝臟炎症，通常透过受污染的水或食用未煮熟的动物肉（尤其是猪肉）传染。根据世界卫生组织 (WHO) 统计，每年约有 2,000 万例 HEV 感染，导致 330 万有症状病例和 44,000 人死亡。这占病毒性肝炎相关死亡率的 3.3%。而戊型肝炎在全球流行。

细分市场前景

全球戊型肝炎诊断测试市场按产品类型、动物类型、应用和最终用户进行细分。根据产品类型，市场分为固定式多层 CT 扫描仪和便携式 CT 扫描仪。根据动物类型，市场分为伴侣动物、牲畜动物和其他动物。根据应用，市场细分为神经病学、肿瘤学、心臟病学、肾臟病学、胃肠病学等。此外，根据最终用户，市场细分为兽医诊所和医院、研究机构等。酶联免疫吸附测定 (ELISA) 子类别预计将占据技术领域的很大一部分市场份额。这一增长可归因于医院广泛采用诊断肝炎的程序。

预计血清学测试细分市场将在全球戊型肝炎诊断测试市场中占据相当大的份额

在疾病类型中，血清学检测子细分市场预计将在全球戊型肝炎诊断检测市场中占据相当大的份额。细分市场的成长归因于血清学检测的进步。酵素免疫分析 (EIA) 测试的引入，特别是能够识别 IgM 和 IgG 抗 HEV 抗体的被动 EIA 技术，强调了戊型肝炎诊断血清学测试的技术进步。 IgM 和 IgG 抗体之间的区分有助于识别现代或先前的疾病。据 MDPI 称，2021 年 1 月，用于检测 HEV 感染的血清学检测包括酵素免疫分析（EIA）检测。间接 EIA 测定能够检测 IgM 和 IgG 抗 HEV 抗体。 IgM 抗 HEV 抗体最早出现，显示急性或近期感染，而 IgG 抗 HEV 抗体持续数年，显示近期或先前感染。然而，这些检测的灵敏度和特异性可能有所不同，并且可能与其他病毒（如 CMV 和 EBV）发生交叉反应。万泰试验是最常用的 IgM 检测商业 ELISA 试验，在 EIA 试验中以其高灵敏度和特异性而闻名。

区域展望

全球戊型肝炎诊断测试市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国） 、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于医疗保健设施的不断增长、适用的製造商数量巨大以及政府参与度和专业社区的增加，预计亚太地区将在全球市场中占据显着份额。

北美地区预计全球戊型肝炎诊断测试市场将以显着的CAGR成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。区域增长归因于该地区诊断测试的发展。这些研究的见解推动了诊断测试的发展，这些测试能够识别戊型肝炎感染的多种标记物，例如抗体和病毒RNA，以便提供更完整的诊断图并帮助了解疾病动态。据 MDPI 称，2023 年 10 月，对爱沙尼亚 1002 份供体血清中抗 HEV IgG 和 IgM 抗体以及病毒 RNA 的流行情况进行了分析。其中，48份血清（4.8%）检测出抗HEV抗体呈阳性，其中40份（4%）含有抗HEV IgG，15份（1.5%）含有抗HEV IgM。此外，7 名捐赠者同时拥有这两类抗体。然而，在任何血清样本中均未检测到 HEV RNA。然而，随着年龄的增长，抗 HEV IgG 带因者的发生率较高，统计分析发现感染风险变数与抗 HEV 抗体盛行率之间没有统计上的显着关联。

市场参与者展望

服务于戊型肝炎诊断测试市场的主要公司包括 Bio-Rad Laboratories, Inc.、Danaher Corp.、Diasorin SpA、EKF Diagnostics Holdings plc、ELITech Group 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2022年9月，吉利德科学公司与布莱根妇女医院、哈佛医学院和贝斯以色列女执事医疗中心合作。这项多年计画包括一项分阶段的方法，旨在解决越南和菲律宾这两个乙型肝炎和丙型肝炎流行率很高的国家的基础医疗机构的病毒性肝炎诊断和管理障碍。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球戊型肝炎诊断测试市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Abbott
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Becton, Dickinson, and Co.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • BIOMERIEUX
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按疾病类型分類的全球戊型肝炎诊断测试市场
    • 血清学测试
    • 分子测试
    • 免疫测定
    • 现场护理测试
  • 按技术分類的全球戊型肝炎诊断测试市场
    • 酵素连结免疫吸附测定法 (ELISA)
    • 快速诊断测试 (RDT)
    • 新一代定序 (NGS)
    • 核酸扩增检验 (NAAT)
  • 全球戊型肝炎诊断测试市场（按最终用户）
    • 医院和诊所
    • 诊断实验室
    • 公共卫生机构和研究机构

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • Diasorin S.p.A.,
  • EKF Diagnostics Holdings plc
  • ELITech Group
  • F. Hoffmann-La Roche Ltd
  • Grifols
  • Hologic, Inc.
  • InBios International, Inc.
  • Mast Group Ltd.
  • QIAGEN GmbH
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
Product Code: OMR2028071

Global Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report by Disease Type (Serology Tests, Molecular Tests, Immunoassays, and Point-of-Care Tests), by Technology (Enzyme-Linked Immunosorbent Assay, Rapid Diagnostic Tests, Next-Generation Sequencing, and Nucleic Acid Amplification Tests) and by End User (Hospitals and Clinics, Diagnostic Laboratories, and Public Health Agencies and Research Institutions), Forecast Period (2024-2031)

The global hepatitis e diagnostic tests market is anticipated to grow at a CAGR of 7.40% during the forecast period (2024-2031). The market's growth is attributed to the demand for global health concern. The global prevalence and significance of Hepatitis E as a major public health concern motivate continued growth and acceptance of diagnostic tests to effectively manage and minimize the disease's impact on public health. According to the National Institute of Health (gov.) in May 2023, the hepatitis E is a liver inflammation caused by the hepatitis E virus (HEV), that is commonly transmitted through contaminated water or the consumption of undercooked animal meat, particularly pork. According to the World Health Organization (WHO), there are approximately 20 million HEV infections annually, resulting in 3.3 million symptomatic cases and 44,000 deaths. This accounts for 3.3% of viral hepatitis-related mortalities. While hepatitis E is prevalent globally.

Segmental Outlook

The global hepatitis E diagnostic tests market is segmented on the product type, animal type, application, and end user. Based on the product type, the market is sub-segmented into stationary multi-slice CT scanner, and portable CT scanner. Based on the animal type, the market is sub-segmented into companion animal, livestock animal, others. Based on the application, the market is sub-segmented into neurology, oncology, cardiology, nephrology, gastroenterology, and others. Furthermore, on the basis of end-user, the market is sub-segmented into veterinary clinics and hospitals, research institutes, and others. The enzyme-linked immunosorbent assay (ELISA) subcategory is expected to capture a significant portion of the market share within the technology segment. The growth can be attributed to the widespread adoption of the procedure to diagnose hepatitis in hospitals.

The Serology Tests Sub-Segment is Anticipated to Hold a Considerable Share of the global Hepatitis E Diagnostic Tests Market

Among the disease type, the serology tests sub-segment is expected to hold a considerable share of the global Hepatitis E Diagnostic Tests market. The segmental growth is attributed to the advancement in serological testing. The introduction of Enzyme Immunoassay (EIA) testing, specifically passive EIA techniques capable of identifying IgM and IgG anti-HEV antibodies, emphasizes technological advances in serology tests for Hepatitis E diagnosis. The division between IgM and IgG antibodies aids in the identification of modern or previous diseases. According to the MDPI, in January 2021, serological tests used to detect HEV infection include enzyme immunoassay (EIA) tests. Indirect EIA assays are capable of detecting IgM and IgG anti-HEV antibodies. IgM anti-HEV antibodies are the first to appear, indicating an acute or recent infection, while IgG anti-HEV antibodies persist for years, suggesting a recent or past infection. However, the sensitivity and specificity of these assays can vary, and there is a potential for cross-reactivity with other viruses such as CMV and EBV. The Wantai test is the most commonly used commercial ELISA test for IgM detection, known for its high sensitivity and specificity among EIA tests.

Regional Outlook

The global hepatitis E diagnostic tests market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing healthcare facilities, a significant amount of applicable manufacturer and rise in government involvement and proficient communities.

The North America Region is Expected to Grow at a Significant CAGR in the global Hepatitis E Diagnostic Tests Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the diagnostic test development across the region. Insights from such studies motivate the development of diagnostic tests capable of identifying numerous markers of Hepatitis E infection, such as antibodies and viral RNA, in order to provide a more complete diagnostic picture and aid in understanding disease dynamics. According to the MDPI, in October 2023, the prevalence of anti-HEV IgG and IgM antibodies, as well as viral RNA, was analyzed in 1002 donor sera in Estonia. Out of these, 48 sera (4.8%) tested positive for anti-HEV antibodies, with 40 (4%) containing anti-HEV IgG and 15 (1.5%) containing anti-HEV IgM. Additionally, 7 donors had antibodies of both classes simultaneously. However, no HEV RNA was detected in any of the blood serum samples. However for a higher incidence of anti-HEV IgG carriers with age, statistical analysis identified no statistically significant associations between infection risk variables and the prevalence of anti-HEV antibodies.

Market Players Outlook

The major companies serving the hepatitis E diagnostic tests market includes Bio-Rad Laboratories, Inc., Danaher Corp., Diasorin S.p.A., EKF Diagnostics Holdings plc, ELITech Group, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2022,Gilead Sciences, Inc. collaborated with Brigham and Women's Hospital, Harvard Medical School and Beth Israel Deaconess Medical Center. This multi-year program comprises a staged approach to addressing barriers to viral hepatitis diagnosis and management in basic healthcare authorities in Vietnam and the Philippines, two countries with significant hepatitis B and C prevalence.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global hepatitis E diagnostic tests market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Becton, Dickinson, and Co.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. BIOMERIEUX
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Hepatitis E Diagnostic Tests Market by Disease Type
    • 4.1.1. Serology Tests
    • 4.1.2. Molecular Tests
    • 4.1.3. Immunoassays
    • 4.1.4. Point-of-Care Tests
  • 4.2. Global Hepatitis E Diagnostic Tests Market by Technology
    • 4.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 4.2.2. Rapid Diagnostic Tests (RDTs)
    • 4.2.3. Next-Generation Sequencing (NGS)
    • 4.2.4. Nucleic Acid Amplification Tests (NAAT)
  • 4.3. Global Hepatitis E Diagnostic Tests Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Laboratories
    • 4.3.3. Public Health Agencies and Research Institutions

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bio-Rad Laboratories, Inc.
  • 6.2. Danaher Corp.
  • 6.3. Diasorin S.p.A.,
  • 6.4. EKF Diagnostics Holdings plc
  • 6.5. ELITech Group
  • 6.6. F. Hoffmann-La Roche Ltd
  • 6.7. Grifols
  • 6.8. Hologic, Inc.
  • 6.9. InBios International, Inc.
  • 6.10. Mast Group Ltd.
  • 6.11. QIAGEN GmbH
  • 6.12. Siemens Healthineers
  • 6.13. Sysmex
  • 6.14. Thermo Fisher Scientific Inc.
  • 6.15. VWR International, LLC

LIST OF TABLES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 2. GLOBAL SEROLOGY TESTS HYSTEROSCOPE HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 10. GLOBAL OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION,2023-2031 ($ MILLION)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 16. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 17. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 18. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 19. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 20. NORTH AMERICAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 21. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 22. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 23. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 24. EUROPEAN HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 25. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 26. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 27. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 28. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 30. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2023-2031 ($ MILLION)
  • 31. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2023-2031 ($ MILLION)
  • 32. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY DISEASE TYPE, 2023 VS 2031(%)
  • 2. GLOBAL SEROLOGY TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 3. GLOBAL MOLECULAR TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 4. GLOBAL IMMUNOASSAYS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 5. GLOBAL POINT-OF-CARE TESTS HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 6. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY TECHNOLOGY, 2023 VS 2031(%)
  • 7. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN RAPID DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 9. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NEXT-GENERATION SEQUENCING TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 10. GLOBAL HEPATITIS E DIAGNOSTIC TESTS IN NUCLEIC ACID AMPLIFICATION TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 11. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY END USER, 2023 VS 2031(%)
  • 12. GLOBAL HEPATITIS E DIAGNOSTIC TESTS HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 13. GLOBAL HEPATITIS E DIAGNOSTIC TESTS DIAGNOSTIC LABORATORIES MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 14. GLOBAL HEPATITIS E DIAGNOSTIC TESTS PUBLIC HEALTH AGENCIES AND RESEARCH INSTITUTIONS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 15. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET SHARE BY REGION, 2023 VS 2031(%)
  • 16. US HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 17. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 18. UK HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 19. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 20. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 21. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 22. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 23. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 24. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 25. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 26. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 27. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)
  • 29. REST OF THE WORLD HEPATITIS E DIAGNOSTIC TESTS MARKET SIZE, 2023-2031 ($ MILLION)